Keywords: لیناگلیپتین; Vildagliptin; Drug-induced liver injury; Hypersensitivity; Covalent binding; Nucleophilic trapping agents; ALG; alogliptin; ANG; anagliptin; CRP; C-reactive protein; CYP; cytochrome P450; DILI; drug-induced liver injury; DLST; drug-induced lymphocyte stim
مقالات ISI لیناگلیپتین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: لیناگلیپتین; Derivative spectrophotometry; Ratio derivative; Linagliptin; Metformin hydrochloride;
Keywords: لیناگلیپتین; Canagliflozin; Empagliflozin; Extended ratio subtraction; Linagliptin; Metformin; Ratio difference; UV spectrophotometry; Validation;
Keywords: لیناگلیپتین; Hypothermic preservation; Linagliptin; Dynamin-related protein 1; NADPH oxidase2; Calmodulin-dependent protein kinase II;
Keywords: لیناگلیپتین; Allodynia; Chronic post-ischemia pain; Dipeptidyl peptidase-4 inhibitors; Hyperalgesia; Linagliptin; Nociception;
Keywords: لیناگلیپتین; Linagliptin; Indole-3-carbinol; Polycystic ovarian syndrome; Rats;
Keywords: لیناگلیپتین; Type 2 diabetes; Linagliptin; Metformin; Combination therapy; Asian population;
Keywords: لیناگلیپتین; Linagliptin; Dipeptidyl peptidase-4 inhibitor; Type 2 diabetes mellitus; Coronary artery disease; Drug safety; Heart failure;
Keywords: لیناگلیپتین; Dipeptidyl peptidase 4 (DPP-4) inhibition; linagliptin; kidney disease end points; albuminuria; renal function; renal risk; type 2 diabetes mellitus (T2DM); hyperglycemia; glucose control; glucose-lowering therapy; pooled analysis;
Keywords: لیناگلیپتین; DPP4-inhibitor; hypoglycemia; linagliptin; safety; type 2 diabetes mellitus;
Keywords: لیناگلیپتین; diabetes; DPP-4 inhibitor; drug-drug interaction; empagliflozin; linagliptin; SGLT2 inhibitor;
Keywords: لیناگلیپتین; cardiovascular risk; DPP-4 inhibitor; insulin; linagliptin; type 2 diabetes mellitusrisque cardiovasculaire; inhibiteur de la DPP-4; insuline; linagliptine; diabète sucré de type 2
A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers
Keywords: لیناگلیپتین; ALG; alogliptin; AUC0-t and AUC0-â; the areas under the plasma concentration-time curve; Cmax; maximum plasma concentration; DPP-IV; dipeptidyl peptidase; ER; extraction recovery; GIP; glucose-dependent insulinotropic polypeptide; GLP 1; glucagon-
A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial
Keywords: لیناگلیپتین; Incretin; DPP4 inhibitors; long-term care; nursing home; skilled nursing facilities; glargine; linagliptin; basal insulin; hospital hyperglycemia; older adults; diabetes;
Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1
Keywords: لیناگلیپتین; Linagliptin; l-dopa; Carbidopa; Parkinsonism; Behavioural changes; Mice;
Neuroprotective effect of linagliptin against cuprizone-induced demyelination and behavioural dysfunction in mice: A pivotal role of AMPK/SIRT1 and JAK2/STAT3/NF-κB signalling pathway modulation
Keywords: لیناگلیپتین; Cuprizone; Demyelination; Multiple sclerosis; Linagliptin; SIRT1; AMPK;
Solvothermal synthesis of N-doped graphene supported PtCo nanodendrites with highly catalytic activity for 4-nitrophenol reduction
Keywords: لیناگلیپتین; Solvothermal method; Nitrogen-doped graphene; Nanodendrites; Linagliptin; 4-Nitrophnol;
Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes
Keywords: لیناگلیپتین; Diabetes; Endothelin; Linagliptin; TLR2; Cerebrovasculature;
Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice
Keywords: لیناگلیپتین; DPP-4 inhibitor; Linagliptin; High fat diet; MCAO; Stroke; GLP-1
Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats
Keywords: لیناگلیپتین; GLP-1; glucagon-like peptide 1; DPP-4; dipeptidyl peptidase-4; ZDF; Zucker diabetic fatty; B1; baseline blood-sampling time-point before drug treatment; B2; baseline blood-sampling time-point 60Â min after treatment but before the sucrose or glucose load;
Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials
Keywords: لیناگلیپتین; DPP-4 inhibitor; HbA1c; linagliptin; type 2 diabetes mellitus;
Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin
Keywords: لیناگلیپتین; DPP-4 inhibitors; Hybrid compound design; Linagliptin; Alogliptin; Diabetes
Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization
Keywords: لیناگلیپتین; DPP-IV inhibitor; Type 2 diabetes; Linagliptin; Pharmacophore hybridization; Hit-to-lead optimization;
Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials
Keywords: لیناگلیپتین; Combination therapy; DPP-4 inhibitor; Linagliptin; Poor glycemic control; Type 2 diabetes mellitus
Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux
Keywords: لیناگلیپتین; Linagliptin; Dipeptidyl peptidase-4 inhibitor; Transport; Pharmacokinetics; P-glycoprotein; Bile
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
Keywords: لیناگلیپتین; Clinical trial-DPP-4 inhibitor; Alogliptin; Linagliptin; Saxagliptin; Sitagliptin; Vildagliptin; Type 2 diabetes mellitus; ReviewDiabète de type 2; Essai clinique; Inhibiteur de la DPP-4; Alogliptine; Linagliptine; Saxagliptine; Sitagliptine; Vildagliptin
Review of Linagliptin for the Treatment of Type 2 Diabetes Mellitus
Keywords: لیناگلیپتین; diabetes mellitus; dipeptidyl-peptidase 4 inhibitor; linagliptin; type 2 diabetes mellitus
Efficacy and Tolerability of Linagliptin Added to a Sulfonylurea Regimen in Patients With Inadequately Controlled Type 2 Diabetes Mellitus: An 18-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Keywords: لیناگلیپتین; add-on therapy; dipeptidyl peptidase-4 inhibitor; linagliptin; sulfonylurea; type 2 diabetes mellitus;
GLP-1 for type 2 diabetes
Keywords: لیناگلیپتین; GLP-1; DPP-4 inhibition; Type 2 diabetes; Exenatide; Liraglutide; Albiglutide; Taspoglutide; Lixisenatide; Sitagliptin; Vildagliptin; Saxagliptin; Alogliptin; Linagliptin
A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects
Keywords: لیناگلیپتین; bioavailability; DPP-4 inhibitor; food; linagliptin; pharmacokinetics; type 2 diabetes
Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients⁎
Keywords: لیناگلیپتین; BI 1356; dipeptidyl-peptidase-4; incretin; linagliptin; pharmacodynamics; pharmacokinetics; type 2 diabetes
Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
Keywords: لیناگلیپتین; alogliptin; dipeptidyl peptidase-4 (DPP-4) inhibitor; linagliptin; saxagliptin; sitagliptin; vildagliptin